These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 12771643)
1. A bioavailability study in the proposed patient population--with much more needed now. Freedman MD Crit Care Med; 2003 May; 31(5):1588-9. PubMed ID: 12771643 [No Abstract] [Full Text] [Related]
2. Anticoagulation in cirrhosis patients: what don't we know? Northup PG; Intagliata NM Liver Int; 2011 Jan; 31(1):4-6. PubMed ID: 21092072 [No Abstract] [Full Text] [Related]
3. Low-molecular-weight heparin in patients with advanced cirrhosis. Bechmann LP; Sichau M; Wichert M; Gerken G; Kröger K; Hilgard P Liver Int; 2011 Jan; 31(1):75-82. PubMed ID: 20958919 [TBL] [Abstract][Full Text] [Related]
4. Enoxaparin as prophylaxis against thromboembolism after total hip replacement. Pedell L N Engl J Med; 1997 Feb; 336(8):585; author reply 586. PubMed ID: 9036311 [No Abstract] [Full Text] [Related]
5. A comparison of the biological activity of 2 formulations of enoxaparin in 12 healthy volunteers. Sharma V; Madhu S; Natarajan P; Muniyandi G; Jaiswal V; Saxena R Clin Appl Thromb Hemost; 2010 Aug; 16(4):387-93. PubMed ID: 19671565 [TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects. Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405 [TBL] [Abstract][Full Text] [Related]
8. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study. Hammerstingl C; Omran H; Tripp C; Poetzsch B Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817 [TBL] [Abstract][Full Text] [Related]
9. Experience with intravenous enoxaparin in critically ill infants and children. Crary SE; Van Orden H; Journeycake JM Pediatr Crit Care Med; 2008 Nov; 9(6):647-9. PubMed ID: 18838932 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA; Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716 [TBL] [Abstract][Full Text] [Related]
11. The prophylaxis of medical patients for thromboembolism pilot study. Lederle FA; Sacks JM; Fiore L; Landefeld CS; Steinberg N; Peters RW; Eid AA; Sebastian J; Stasek JE; Fye CL Am J Med; 2006 Jan; 119(1):54-9. PubMed ID: 16431185 [TBL] [Abstract][Full Text] [Related]
12. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Martin JL; Fry ET; Sanderink GJ; Atherley TH; Guimart CM; Chevalier PJ; Ozoux ML; Pensyl CE; Bigonzi F Catheter Cardiovasc Interv; 2004 Feb; 61(2):163-70. PubMed ID: 14755805 [TBL] [Abstract][Full Text] [Related]
13. [Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients]. Omran H; Hammerstingl C; Paar WD; Med Klin (Munich); 2007 Oct; 102(10):809-15. PubMed ID: 17928964 [TBL] [Abstract][Full Text] [Related]
14. Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention. Díez JG; Cheong BY; O'Meallie LP; Alt EU J Interv Cardiol; 2004 Oct; 17(5):307-13. PubMed ID: 15491334 [TBL] [Abstract][Full Text] [Related]
15. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety. Kane-Gill SL; Feng Y; Bobek MB; Bies RR; Pruchnicki MC; Dasta JF J Clin Pharm Ther; 2005 Jun; 30(3):207-13. PubMed ID: 15896237 [TBL] [Abstract][Full Text] [Related]
16. Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin. Spinal Cord Injury Thromboprophylaxis Investigators J Trauma; 2003 Jun; 54(6):1111-5. PubMed ID: 12813331 [TBL] [Abstract][Full Text] [Related]
17. Alkanoylsucroses in nasal delivery of low molecular weight heparins: in-vivo absorption and reversibility studies in rats. Yang T; Mustafa F; Ahsan F J Pharm Pharmacol; 2004 Jan; 56(1):53-60. PubMed ID: 14980001 [TBL] [Abstract][Full Text] [Related]